CEO Jacqueline Shea on the potential she sees for INO-3107 and driving progress for #RRP patients. Listen to our financial results conference call here: https://bit.ly/4essJH1
关于我们
INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. Our mission: deliver on the promise of DNA medicine for patients around the world. For more information, visit www.inovio.com.
- 网站
-
https://www.inovio.com
INOVIO Pharmaceuticals, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Plymouth Meeting，PA
- 类型
- 上市公司
- 领域
- DNA medicines、DNA plasmids、HPV-associated disease、cancer、infectious diseases、coronaviruses、immuno-oncology、dMAb (DNA-encoded monoclonal antibodies)、immunotherapy、DNA vaccines、high-risk HPV、cervical dysplasia、cervical cancer、cervical HSIL、vulvar HSIL、anal HSIL、recurrent respiratory papillomatosis (RRP)、HPV-associated cancers、head and neck cancer、glioblastoma、prostate cancer、Ebola、Zika、MERS、COVID-19、HIV、Lassa、T cells、SynCon、CELLECTRA和electroporation
地点
INOVIO Pharmaceuticals, Inc.员工
-
Nicole Rich
Senior Director - Commercial Development at INOVIO Pharmaceuticals, Inc.
-
Laurent Humeau
Chief Scientific Officer and Executive Vice President of Research and Development
-
Shawn Bridy, MA, MBA
Senior Vice President, Business Development at INOVIO Pharmaceuticals, Inc.
-
ROBERT GUTHRIE
Manufacturing Electrical Engineer in Pharmaceutical Industry
动态
-
INOVIO reports third quarter financial results and operational highlights – read more here: https://bit.ly/4hHudQF Key updates include: ? Continued progress on INO-3107, targeting mid-2025 BLA submission ? New immunology data for INO-3107?
-
-
INOVIO announces important immunology data corresponding to a reduction of surgeries for #RRP patients observed in Phase 1/2 trial – read more for details: https://bit.ly/4fJltaN #IPVC2024
-
-
Dr. Dave Liebowitz will join other industry leaders and visionaries next week at the Vaccines Summit in Boston, MA to give a keynote address on the power and versatility of INOVIO’s #DNAMedicine platform.
-
-
Dr. Matthew Morrow and Dr. Jeffrey Skolnik will be sharing new data on INO-3107, our lead candidate for the treatment of #RRP at #IPVC2024 – the leading international platform for sharing cutting-edge HPV research.
-
-
INOVIO will be sharing new data and highlighting the versatility of our #DNAMedicine platform at upcoming scientific conferences – details here: https://bit.ly/3O1bIsJ
-
-
Our business development team will be at #BIOEurope next week to connect with innovators from across the globe and talk about the potential of #DNAMedicine. Reach out through the partnering system if you want to connect in Stockholm!?
-
-
How does INOVIO recognize #BreastCancerAwareness month? With a deep dive into the science of cancer prevention and the potential for #DNAMedicine to shift the way we treat and prevent breast cancer. We were honored to welcome two experts from Penn Medicine, University of Pennsylvania Health System for a virtual visit this month: Dr. Susan Domchek from the Penn Medicine Basser Center for BRCA & Dr. Robert Vonderheide from the Abramson Cancer Center talked about BRCA mutations, cancer risk and their groundbreaking research with INOVIO DNA medicine candidate INO-5401.?
-
-
International Society for Vaccines - ISV 2024, Seoul, South Korea. Day 2 also had a very inspiring session on “Adjuvant and vaccine delivery”. Dr. Birgit Weinberger, Universit?t Innsbruck, Austria, presented an overview of contributions of adjuvant in developing efficacious vaccine for ever growing adult population. Dr. Mike Sumner from INOVIO Pharmaceuticals, Inc. presented exciting new data from an early phase clinical trial for INO 3107 an adjuvanted therapy in adults with recurrent respiratory papillomatosis caused by HPV-6 and HPV-11. Additional exciting pre-clinical findings were presented on immune contraceptive for overpopulation of certain animals in wild, a combination adjuvant therapy for cancer immunotherapy, a development of a novel synthetic saponin adjuvant for protein vaccines and an adjuvanted vaccine for heroin and Fentanyl. These talks were followed by many questions and comments from attendees. Stay tuned for more updates from the congress! #ISV #ISV2024 #VaccinesWork #seoul #VaccinesSaveLives #ProtectedTogether
-
-
-
-
-
+4
-
-
See you at #WVCEU! Don’t miss Dr. Dave Liebowitz, SVP Early Stage Clinical Development, at the pre-congress workshop on platform technology, where he’ll be discussing the power and potential of #DNAMedicine.??
-